The clot stabilizer drug tranexamic acid can be administered safely to a wide range of patients with traumatic bleeding and should not be restricted to the most severe cases, a study published on bmj.com today suggests.
Previous studies have already shown that tranexamic acid significantly reduces death from all causes, without increasing the risk of thrombotic adverse events (formation of a blood clot in a blood vessel). As such, tranexamic acid is being incorporated into trauma protocols around the world, but these tend to focus on the most severely injured.